Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
Clinical trial NCT05463133 · RECRUITING
Trial details
- NCT number
- NCT05463133
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-08
- Primary completion
- 2032-12-31
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.